Drugs / TDM-180935
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05525468 | Feb → Aug 2023 | — | Technoderma Medicines Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06363461 | Apr 2024 → Mar 2025 | atopic eczema | Technoderma Medicines Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDM-180935 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05525468 ↗ |
| Route | Topical | “Following Topical Administration” NCT05525468 ↗ |